---
name: Crystec Limited (CrystecPharma)
slug: crystecpharma
site: cdmo
website_domain: crystecpharma.com
summary: Crystec Limited (CrystecPharma) is a pharmaceutical technology company that offers its mSAS® supercritical-fluid particle engineering platform to improve the bioavailability, stability and delivery of small and large molecule therapeutics. Its work is aimed at clients developing new and existing medicines. Headquartered in Bradford, United Kingdom.
tagline: Transforming the performance of medicines through advanced particle engineering
founded_year: 
employee_count_band: 
employee_count_label: 
parent_name: 
parent_slug: 
hq_country: GB
tier2_domain_verified: false
updated_at: 2026-11-19T07:00:54.740Z
services_count: 4
modalities_count: 5
indications_count: 1
locations_count: 4
review_signal_gate: closed
generated_by: BioBM Editorial AI
---

# Crystec Limited (CrystecPharma)

Transforming the performance of medicines through advanced particle engineering

Listed on cdmo.directory.

## Summary

Crystec Limited (CrystecPharma) is a pharmaceutical technology company that offers its mSAS® supercritical-fluid particle engineering platform to improve the bioavailability, stability and delivery of small and large molecule therapeutics. Its work is aimed at clients developing new and existing medicines. Headquartered in Bradford, United Kingdom.

## At a glance

- HQ country: GB

## Services

- Solid-State Chemistry & Polymorph Screening
- Inhalation & Nasal Dosage Manufacturing
- Process Development
- Formulation Development

## Modalities

- Small Molecule
- Biologics (Monoclonal Antibodies)
- Biologics (Other)
- Oligonucleotide
- Peptide

## Indications

- Respiratory

## Locations

- Bradford (Headquarters), Bradford, United Kingdom
- Tianjin, Tianjin, China
- Hangzhou (Inhalatec), Hangzhou, China
- Lugano (Inhalis), Lugano, Switzerland

## Long description

## Overview

CrystecPharma describes itself as a global pharmaceutical technology company focused on transforming the performance of medicines. Its proprietary mSAS® (modified Supercritical Anti-Solvent) particle engineering platform is presented as a way to optimise new and existing small and large molecule therapeutics.

## Technology and applications

The website describes mSAS® as a single-step process for engineering particles to improve:

- Dissolution and solubility of poorly soluble drugs, including increasing surface area, reducing agglomeration, and producing new solid-state forms, co-crystals or stabilised amorphous forms.
- Inhaled therapies, with particle size and shape designed for aerosolisation.
- Chemical and physical stability, including residue-free particles that resist moisture and higher temperatures.
- Formulation simplification, by producing particles that combine the components needed for a medicine to perform.
- Biomolecule processing, including peptides, proteins, antibodies and oligonucleotides, as free-flowing powders.
- Natural product simplification and fine tuning of medicine components.

## Sustainability

The site states that, on average, the mSAS® process uses 27% less solvent than micronisation and 80% less than spray drying, with an average 95% yield and improved energy efficiency relative to spray drying and micronisation.

## Clients and partners

The website refers to "large and smaller clients" and lists scientific centres in Bradford (UK, headquarters), Tianjin (China), Hangzhou (China, Inhalatec) and Lugano (Switzerland, Inhalis). It also describes Prevista AI, a tool that assesses compound compatibility with the mSAS® technology.

## Similar companies

- [PharmaBlock](/companies/pharmablock) (Solid-State Chemistry & Polymorph Screening, Process Development) — [Compare](/compare/crystecpharma/pharmablock)
- [Lupin Limited](/companies/lupin) (Inhalation & Nasal Dosage Manufacturing, Process Development) — [Compare](/compare/crystecpharma/lupin)
- [CordenPharma](/companies/cordenpharma) (Solid-State Chemistry & Polymorph Screening, Inhalation & Nasal Dosage Manufacturing) — [Compare](/compare/cordenpharma/crystecpharma)
- [Porton](/companies/portonpharma) (Solid-State Chemistry & Polymorph Screening, Process Development) — [Compare](/compare/crystecpharma/portonpharma)
- [Gannet Biochem](/companies/gannetbiochem) (Process Development, Formulation Development) — [Compare](/compare/crystecpharma/gannetbiochem)
- [Veranova](/companies/veranova) (Solid-State Chemistry & Polymorph Screening, Process Development) — [Compare](/compare/crystecpharma/veranova)
- [AustinPx](/companies/austinpx) (Solid-State Chemistry & Polymorph Screening, Process Development) — [Compare](/compare/austinpx/crystecpharma)
- [Sinopep-Allsino Biopharmaceutical Co., Ltd.](/companies/sinopep) (Process Development, Formulation Development) — [Compare](/compare/crystecpharma/sinopep)

_Profile last updated: 2026-11-19T07:00:54.740Z. Profile facts may include AI-assisted enrichment._

Auto-generated by BioBM Editorial AI for machine-readable profile access.